Vaxcyteの空売り状況は、投資家がVaxcyteの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Vaxcyte (NASDAQ:PCVX) 株価情報, 空売り情報

Vaxcyte

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Vaxcyte Inc

WIIM

MRIN

Marin Software shares are trading lower after the company announced it received a Nasdaq letter regarding a late 10-K form filing.

LAFAYETTE, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=t_8_0md_EGEbupax57iiPEEURxFBI8IFZKQx8Ne3xx_fB6wagihLsHwDjUstDLpHBUPDRcDdgU702Lt-10creDZvhrHwiD9sv5cwe4cjA9w=">Wabash (NYSE:</a><a href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>), a leader in end-to-end supply chain solutions for the transportation, logistics and infrastructure markets, today announced a strategic partnership with UP.Labs, a pioneering corporate venture lab, to co-develop Wabash Venture Lab and two startups focused on enhancing configuration workflows and aftermarket parts optimization across Wabash's technology platforms.

News

Wabash Announces Strategic Partnership With UP.Labs To Co-Develop Wabash Venture Lab And Two Startups

SNOA

Sonoma Pharmaceuticals shares are trading higher after the company announced the registration and launch of new products in the UK.

PennyMac Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.39 by 102.56 percent. This is a 102.56 percent decrease over earnings of $0.39 per share from the same period last year. The company reported $44.465 million in sales this quarter. This is a 40.08 percent decrease over sales of $74.205 million the same period last year.

Earnings

Earnings Misses

PennyMac Mortgage Q1 2025 GAAP EPS $(0.01) Misses $0.39 Estimate, Net investment income $44.465M Down From $74.205M YoY

LAKE FOREST, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=nKSe90CJPlBNC4wfhYLsF5aGQfbR1_0RKkPnuSpFyKk2q-riU6Cp3877xtbfic9FqsepzGfnb2NAgVcV_chrwg==">Del Taco</a> is debuting a bold new brand campaign and the launch of three highly craveable new El Big Boxes that offer consumers unbeatable value.
Del Taco's new look and feel embraces its California roots while celebrating its innovative, one-of-a-kind spirit in bold and unexpected ways. This isn't just about where Del Taco comes from, it's about what Del Taco stands for. With signature Mexican menu items like tacos, burritos and quesadillas, alongside American classics like burgers, fries and shakes, Del Taco delivers favorites in unexpected ways.
"Our refreshed look and voice reflect who we are at our core — innovative, authentic and unapologetically different," said Sarah McAloon, Senior Vice President and Chief Administration Officer. "This rebrand allows us to continue embracing the unique spirit that's always made Del Taco stand out, while delivering unforgettable moments, fresh and delicious Ameri-Mex flavors and even more value to our guests."

JACK

Del Taco Releases Brand Refresh And New El Big Boxes

JP Morgan analyst Tycho Peterson maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and lowers the price target from $280 to $260.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Danaher, Lowers Price Target to $260

BofA Securities analyst Shaun C. Kelley upgraded Sportradar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) from Underperform to Buy, <a href="https://www.benzinga.com/quote/SRAD/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast to $28 from $12.</a>
Kelley writes that the decision to upgrade Sportradar was driven by three main factors: growing confidence in the company's revenue trajectory, improved clarity on costs and potential for margin expansion, and additional upside from its IMG Arena deal, as well as increasing integration of AI. While risks remain—particularly limited visibility outside the U.S. and a relatively high valuation—the analyst highlights that the company is well-positioned.
The primary concern had been that rising sports rights costs would weigh on margins and cash flow, but recent contract renewals in 2023 and 2024 appear to have alleviated that pressure, Kelley notes.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44925313/tesla-q1-earnings-preview-shareholders-analysts-want-answers-on-guidance-tariffs-fsd-and-more" rel="noreferrer noopener">Tesla Q1 Earnings Preview: Shareholders, Analysts Want Answers On Guidance, Tariffs, FSD And More</a>
With strong revenue trends and continued cost control, the analyst projects that margins will improve steadily in the coming years, making the recent uptick in the stock more likely to be sustained.
According to Kelley, Sportradar&#8217;s latest Analyst Day guidance points to a projected compound annual growth rate of approximately 15% through 2027.
This outlook is underpinned by an expected 10% baseline market expansion, along with gains from increasing its take rate through product upselling to existing clients.
A comparison with global B2C gaming companies reveals that Sportradar is growing in tandem with the U.S. market and even outperforming broader international trends, which suggests that the company can maintain mid- to high-single-digit organic growth outside the U.S. despite &#8220;market maturity&#8221; abroad.
The analyst sees further upside potential from the recent IMG Arena acquisition and broader adoption of AI.
These opportunities could unlock new revenue streams by leveraging Sportradar's extensive data assets to benefit sports leagues, media outlets, and bettors, while also driving efficiencies and cost savings in data collection and software operations.
Kelley raised EBITDA projections for Sportradar by 6% for 2025 and 10% for 2026, reflecting improved confidence in the company's financial trajectory.
However, the analyst also flagged a few ongoing risks, including limited geographic and customer transparency outside the U.S., which could affect predictability in international performance.
Price Action: SRAD shares are trading higher by 7.61% to $24.79 at last check on Tuesday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44932220/4-bank-stocks-to-buy-as-earnings-soar" target="_blank" rel="noreferrer noopener">4 Bank Stocks To Buy As Earnings Soar</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

Trading Ideas

General

SRAD

Sportradar Stock Soars As Analyst Sees 15% Growth, AI Upside

<a href="https://www.bloomberg.com/news/articles/2025-04-22/apollo-blackstone-lead-4-billion-loan-for-boeing-unit-takeover">https://www.bloomberg.com/news/articles/2025-04-22/apollo-blackstone-lead-4-billion-loan-for-boeing-unit-takeover</a>&nbsp;

Financing

Asset Sales

Bloomberg Reported Apollo, Blackstone Lead $4B Loan For Boeing Unit Takeover

National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.76 by 17.11 percent. This is a 23.17 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $102.07 million which missed the analyst consensus estimate of $107.46 million by 5.02 percent. This is a 0.34 percent increase over sales of $101.72 million the same period last year.

NBHC

National Bank Holdings Q1 Adj. EPS $0.63 Misses $0.76 Estimate, Sales $102.07M Miss $107.46M Estimate

Dividends

OTIS

Otis Worldwide Increases Quarterly Dividend From $0.39 To $0.42 per Share

PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $1.42 per share which missed the analyst consensus estimate of $2.67 by 46.82 percent. The company reported quarterly sales of $430.903 million which missed the analyst consensus estimate of $534.654 million by 19.41 percent. This is a 40.97 percent increase over sales of $305.660 million the same period last year.

PFSI

PennyMac Financial Servs Q1 2025 GAAP EPS $1.42 Misses $2.67 Estimate, Sales $430.903M Miss $534.654M Estimate

Management

OPENLANE Names Brad Herring As Chief Financial Officer Effective May 27, 2025.

MetLife, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) today announced that its board of directors has declared a second quarter 2025 common stock dividend of $0.5675 per share, an increase of 4.1% from the first quarter common stock dividend of $0.545 per share. MetLife has increased its common stock quarterly dividend at a 9.0% compound annual growth rate since 2011.
The dividend will be payable on June 10, 2025, to shareholders of record as of May 6, 2025.

MetLife Hikes Q2 Common Stock Dividend by 4.1% To $0.5675/Shr From $0.545/Shr in Q1

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score
Treatment with Cobenfy and an atypical antipsychotic showed a numerical improvement compared to treatment with placebo and an atypical antipsychotic
Cobenfy's safety and tolerability profile as an adjunctive therapy was consistent with previous monotherapy trials
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54241943&amp;newsitemid=20250422959331&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=056617e9b2521edad2ea6ceaeb6ccdef">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the primary endpoint (P = 0.11). Preliminary analyses suggest that Cobenfy as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical antipsychotic for certain patients. In a post-hoc subgroup analysis there was a notable difference in response between subjects treated with risperidone as a background therapy compared with the remaining subjects treated with other background antipsychotics (non-risperidone). The initial analyses showed:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6" rowspan="1">PANSS, PSP and CGI-S Change from Baseline by Treatment Group</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Endpoint</td>
<td colspan="1" rowspan="1">Cobenfy + APD</td>
<td colspan="1" rowspan="1">Placebo + APD</td>
<td colspan="1" rowspan="1">LSMD (95% CI)</td>
<td colspan="1" rowspan="1">
&nbsp;
p-value
</td>
</tr>
<tr>
<td colspan="2" rowspan="1">mITT Population, N</td>
<td colspan="1" rowspan="1">190</td>
<td colspan="1" rowspan="1">196</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Primary Endpoint</td>
<td colspan="1" rowspan="1">Change in PANSS Total Score LS Mean (SE)</td>
<td colspan="1" rowspan="1">
-14.3
&nbsp;
(1.01)
</td>
<td colspan="1" rowspan="1">
-12.2
&nbsp;
(0.98)
</td>
<td colspan="1" rowspan="1">-2.0 (-4.5, 0.5)</td>
<td colspan="1" rowspan="1">0.11</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Key Secondary Endpoint</td>
<td colspan="1" rowspan="1">Change in PSP Score LS Mean (SE)</td>
<td colspan="1" rowspan="1">
5.3
(0.75)
</td>
<td colspan="1" rowspan="1">
5.9
(0.73)
</td>
<td colspan="1" rowspan="1">-0.6 (-2.4, 1.2)</td>
<td colspan="1" rowspan="1">0.52&#x2A;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Secondary Endpoint</td>
<td colspan="1" rowspan="1">Change in CGI-S LS Mean (SE)</td>
<td colspan="1" rowspan="1">
-0.6
(0.06)
</td>
<td colspan="1" rowspan="1">
-0.5
(0.06)
</td>
<td colspan="1" rowspan="1">-0.1 (-0.3, 0.04)</td>
<td colspan="1" rowspan="1">0.14&#x2A;</td>
</tr>
<tr>
<td colspan="6" rowspan="1">Post-Hoc Subgroup Analysis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Risperidone</td>
<td colspan="1" rowspan="1">
&nbsp;
Change in PANSS Total Score LS Mean (SE)
</td>
<td colspan="1" rowspan="1">
(N=60)
-11.3
&nbsp;
(2.13)
</td>
<td colspan="1" rowspan="1">
(N=69)
-12.3
&nbsp;
(2.10)
</td>
<td colspan="1" rowspan="1">
&nbsp;
1.1 (-3.7, 5.9)
</td>
<td colspan="1" rowspan="1">
&nbsp;
0.66&#x2A;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-Risperidone</td>
<td colspan="1" rowspan="1">
&nbsp;
Change in PANSS Total Score LS Mean (SE)
</td>
<td colspan="1" rowspan="1">
(N=130)
-15.1
&nbsp;
(1.18)
</td>
<td colspan="1" rowspan="1">
(N=127)
-11.7
&nbsp;
(1.17)
</td>
<td colspan="1" rowspan="1">
&nbsp;
-3.4 (-6.3, -0.5)
</td>
<td colspan="1" rowspan="1">
&nbsp;
0.03&#x2A;
</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">APD = Antipsychotic background drug; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; CGI-S = Clinical Global Impressions Severity Scale; mITT = modified intent-to-treat; SE = Standard Error; LSMD = Least Squares Mean Difference; Non-Risperidone group includes paliperidone, aripiprazole, ziprasidone, lurasidone and cariprazine.&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&#x2A;p-value is nominal, not adjusted for multiplicity&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Bristol Myers Squibb Releases Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy As An Adjunctive Treatment to Atypical Antipsychotics In Adults With Schizophrenia

Vertiv Holdings Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) shares closed <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">higher on Tuesday</a> after the company unveiled a major AI infrastructure initiative, teaming up with NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and artificial intelligence firm iGenius to deploy one of the world's most powerful AI supercomputers.
The project, dubbed "Colosseum," is set to launch in Italy later in 2025 and aims to support mission-critical, sovereign AI workloads <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44918010/igenius-launches-one-of-the-worlds-largest-sovereign-ai-data-centers-leveraging-vertiv-infrastruct" rel="noreferrer noopener">across highly regulated sectors</a>.
Colosseum leverages the NVIDIA DGX SuperPOD framework and will run on NVIDIA's advanced Grace Blackwell Superchips.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44927810/pentair-stock-gains-after-q1-earnings-beat-implements-price-increases-to-offset-tariff-impact" rel="noreferrer noopener">Pentair Stock Gains After Q1 Earnings Beat, Implements Price Increases To Offset Tariff Impact</a>
"The unit of compute is no longer the chip — it's the system, the AI Factory," said&nbsp;the president of Vertiv, EMEA, Karsten Winther.
"Through our collaboration with NVIDIA and visionary AI player iGenius, we are proving the efficiency and system-level maturity of delivering the data center as a unit of compute, unlocking rapid adoption of AI-native power and cooling infrastructure as a catalyst for AI at scale."
Positioned in southern Italy, the facility is designed to meet local sovereignty requirements and adhere to rigorous regulatory standards in industries such as healthcare, finance, and public administration.
Colosseum integrates Vertiv's data center solutions with NVIDIA's AI technologies to enable real-time simulations and faster deployment.
Built on Vertiv's 360AI architecture and tailored for NVIDIA's GB200 NVL72, it offers a scalable, efficient platform for next-generation AI systems.
Vertiv's turnkey AI data center package encompasses power, cooling, monitoring, and maintenance, with initial support for up to 132kW per rack.
Its hybrid design blends modular exterior systems with adaptable interior compute spaces, cutting build times by as much as half when compared to conventional data centers.
The software will be central to Colosseum's functionality, with NVIDIA Mission Control and Vertiv Unify managing real-time coordination of computing, power, and cooling.
This integration links digital twins with physical systems, enabling predictive maintenance, automation, and risk reduction through advanced simulations.
The Colosseum serves as a prototype for scalable sovereign AI data centers worldwide, blending high-density computing with localized control. Vertiv and NVIDIA plan to expand this model with future platforms like the DGX GB300.
Price Action: VRT shares closed higher by 6.29% to $71.82 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44925764/synchrony-financial-q1-earnings-beat-lower-purchase-volume-active-accounts-decline-and-more" target="_blank" rel="noreferrer noopener">Synchrony Financial Q1: Earnings Beat, Lower Purchase Volume, Active Accounts Decline And More</a></li>
</ul>
Photo by T. Schneider via Shutterstock

NVDA

Vertiv, NVIDIA, iGenius Launch AI Supercomputer Project In Italy

MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) reported quarterly earnings of $0.25 per share. This is a 35.9 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $15.04 million which beat the analyst consensus estimate of $12.20 million by 23.31 percent. This is a 12.45 percent increase over sales of $13.38 million the same period last year.

Earnings Beats

MIND

MIND Technology Q4 EPS $0.25 Down From $0.39 YoY, Sales $15.04M Beat $12.20M Estimate

Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) ("Marin," "we," "our," or the "Company"), a provider of digital marketing software for performance-driven advertisers and agencies, on April 16, 2025, received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the delinquency in the timely filing of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024 (the "Form 10-K"), the Company is out of compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC").
In accordance with Nasdaq's listing rules, the Company has 60 calendar days after the date of the Notice, or until June 16, 2025, to submit a plan to regain compliance with respect to the delinquent Form 10-K filing. If the plan is accepted by Nasdaq, Nasdaq can grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until September 29, 2025, to regain compliance.
The Company intends to consider plans to regain compliance with the Rule. However, as previously reported, the Company's board of directors approved the voluntary liquidation and dissolution of the Company (the "Dissolution") and adopted a Plan of Liquidation and Dissolution of the Company (the "Plan of Dissolution"), subject to stockholder approval. If the stockholders approve the Dissolution and the Company proceeds with the Dissolution in accordance with the Plan of Dissolution, the Company's common stock will be delisted from Nasdaq.

Marin Software Incorporated Receives Nasdaq Letter Regarding Late Form 10-K Filing And Continued Listing Requirements

Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.91 by 5.49 percent. This is a 39.13 percent increase over earnings of $0.69 per share from the same period last year.

Range Resources Q1 Adj. EPS $0.96 Beats $0.91 Estimate

TSLA

Tesla Says 'While The Current Tariff Landscape Will Have A Relatively Larger Impact On Our Energy Business Compared To Automotive, We Are Taking Actions To Stabilize The Business In The Medium To Long-Term And Focus On Maintaining Its Health'

Zurn Elkay Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $388.80 million which beat the analyst consensus estimate of $383.80 million by 1.30 percent. This is a 4.01 percent increase over sales of $373.80 million the same period last year.

Comments

Vaxcyte

空売り

Vaxcyte (NASDAQ:PCVX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル